A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients by Flume, Patrick et al.
A Phase 3, Multi-center, Multinational, Randomized, Double-blind, Placebo-
controlled Study to Evaluate the Efficacy and Safety of Levofloxacin 
Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients 
 
Patrick A. Flume1, Donald R. VanDevanter2, Elizabeth E. Morgan3, Michael N. Dudley3, Jeffery 
S. Loutit3, Scott C. Bell4, Eitan Kerem5, Rainald Fischer6, Alan R. Smyth7, Shawn D. Aaron8, 
Douglas Conrad9, David E. Geller10, J. Stuart Elborn11 on behalf of the APT investigators 
 
1Departments of medicine and Pediatrics, Medical University of South Carolina, Charleston, SC 
2Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland Ohio	  
3The Medicines Company, San Diego, CA  
4The Prince Charles Hospital and QIMR Berghofer Medical Research Institute, Queensland, 
Australia 
5Department of Pediatrics, Hadassah Medical Center, Jerusalem, Israel 
6Pneumologische Praxis München-Pasing, Munich, Germany 
7Division of Child Health, Obstetrics & Gynaecology, School of Medicine, University of 
Nottingham, UK.  
8The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. 
9Department of Medicine, University of California, San Diego 
10Florida State University College of Medicine, Orlando, FL  
11Centre for Infection and Immunity, Queens University Belfast, BT9 7AE 
 
Corresponding author: 
Patrick A. Flume, M.D. 
Medical University of South Carolina 
96 Jonathan Lucas Street, 812-CSB 
Charleston, SC 29425 
Office: (843) 792-3167 
Fax: (843) 792-0732 
flumepa@musc.edu 
	  
	  
Word	  count:	  xxxx	  
Key	  words:	  cystic	  fibrosis,	  antibiotics,	  Pseudomonas,	  aerosol,	  fluoroquinolone	  
	   	  
Abstract 
Rationale For patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway 
infection, the use of inhaled antibiotics has become standard of care to suppress the chronic 
airways infection.  There are limited antibiotic options formulated and approved for inhaled use 
and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes 
desirable. Three antibiotic classes are approved for inhaled use: polymyxins, beta-lactams, and 
aminoglycosides. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in 
development for management of chronic P. aeruginosa airways infection in patients with CF. 
Objectives To compare the safety and efficacy of a 28-day course of treatment with LIS 240 mg 
or placebo BID in persons ≥12 years old with CF and chronic P. aeruginosa infection.  
Methods A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28 
days in CF patients ≥12 yrs with chronic P. aeruginosa infection.  Time to exacerbation was the 
primary endpoint.  FEV1 (% predicted) and patient-reported quality of life were among secondary 
endpoints. 	  
Main results Baseline demographics for 330 subjects (LIS=220) were similar although 
significantly more patients randomized to LIS had experienced multiple exacerbations in the year 
prior to study entry. There was no statistically significant difference in protocol-defined 
pulmonary exacerbations between treatment arms.  Relative change in FEV1 % predicted from 
baseline was significantly greater for patients randomized to LIS compared to those randomized 
to placebo ( mean difference 1.31%, p=0.01 [95% CI 0.27, 2.34%]).  LIS was well-tolerated, with 
dysguesia the most frequent adverse event. 
Conclusions LIS did not demonstrate a difference in time to next exacerbation when compared to 
placebo.  Reasons for this result are discussed but may be due to an imbalance in the frequency of 
prior pulmonary exacerbations between the two groups.  An improvement in FEV1 (% predicted) 
at 28 days was observed and LIS was well tolerated. LIS is safe and has a potential role in the 
management of CF patients with chronic P. aeruginosa.  	  
	  
  
INTRODUCTION 
Cystic fibrosis (CF) lung disease is characterized by chronic respiratory tract infection 
with multiple bacterial species frequently dominated by Pseudomonas aeruginosa 1, which has 
been associated with accelerated lung disease progression, increased morbidity, and decreased 
survival 2-4.  Chronic P. aeruginosa infection is typically treated with chronic inhaled antibiotics 
to suppress infection, reduce risk of pulmonary exacerbations, improve quality of life, and 
preserve lung function 5,6.   
Despite the availability of several inhaled antimicrobial classes, there is need for 
additional safe and effective alternative options.  The response to aerosolized tobramycin, as 
assessed by change in spirometry, becomes attenuated after extended exposure, a phenomenon 
that is not explained by selection of bacterial populations with decreased in vitro tobramycin 
susceptibilities7,8. It is likely that a similar attenuation of efficacy will occur for other inhaled 
antimicrobials with extended exposure9. In addition some patients are unable to tolerate particular 
inhaled antibiotic formulations10,11 while others may find an inhaled therapy an excessive 
treatment burden resulting in poor adherence12.  Thus, there is a need for additional inhaled 
antibiotic options; including additional antimicrobial classes to allow for greater rotation of 
therapies and potential for extension of the effective lives of all inhaled antibiotic classes12.   
Antibiotic classes currently approved in many countries for use by inhalation include the 
aminoglycosides (tobramycin), monobactams (aztreonam) and polymyxins (colistimethate) (see 
e-supplement for approved product names).  A separate antibiotic class with high potency and a 
broad spectrum of action, fluoroquinolones, is used extensively as oral and intravenous (IV) 
formulations to treat CF lung disease.  Both the uniqueness of mechanistic class and recognized 
utility of fluoroquinolones in treating CF airway infection make them an attractive candidate for 
inhaled CF therapy.  APT-1026 (levofloxacin inhalation solution, LIS; also formerly known as 
MP-376)13 is a formulation of a fluoroquinolone intended for inhaled use in chronic maintenance 
therapy.  We describe the results of a placebo-controlled study designed to evaluate the efficacy 
and safety of LIS in individuals with CF and chronic P. aeruginosa infection who had previously 
used inhaled tobramycin. 
 
METHODS 
Study Design 
This was a randomized, double-blind, placebo-controlled trial conducted at 97 CF centers 
in USA, Canada, Australia, New Zealand and Israel.  Subjects were recruited between October 
2010 and May 2012.  Eligible patients were randomized 2:1 to receive 28 days of treatment with 
either LIS 240 mg (2.4 mL of a 100 mg/ml of levofloxacin as AP-1026) BID or a 0.9% saline-
based placebo (color matched with riboflavin), with a 28-day follow-up period off therapy (e-
supplement Figure 1).  LIS or placebo was delivered with a PARI investigational eFlow® 
nebulizer.   
The study was conducted in accordance with Good Clinical Practice, as recommended by 
the Declaration of Helsinki and the International Congress of Harmonization Guidelines, and the 
laws and regulations of each study site.  Institutional Review Boards and/or Ethics Committees 
approved the study for each site.  Patients provided written consent or parents provided consent 
for their children prior to undergoing study procedures.   
 
Participants 
Eligible patients were > 12 years of age with documented CF diagnosis, a forced 
expiratory volume in 1 second (FEV1) between 25 and 85 percent of their predicted values using 
Hankinson/NHANES III reference equations 14, chronic airways infection with P. aeruginosa, 
and had received at least three 28-day courses (> 84 days) of inhaled tobramycin inhalation 
solution (TIS) over the 12 months prior to screening.  Chronic P. aeruginosa infection was 
defined as report of a respiratory secretion culture positive for P. aeruginosa in the 12 months 
immediately prior to screening and a positive culture obtained at the screening visit.  Participants 
continued their routine respiratory care and medications during the study.  Patients were not 
permitted to use other antipseudomonal antimicrobials other than Study Drug unless deemed 
necessary by the Investigator to treat a suspected exacerbation. Detailed inclusion and exclusion 
criteria and randomization schema can be found in the e-supplement. 
 
Endpoints 
The primary efficacy endpoint was the time to an exacerbation of CF lung disease.  To 
meet the definition of an exacerbation, patients must concurrently have had changes in >4 of 12 
respiratory signs or symptoms originally described by Fuchs et al 15, independent of an 
investigator decision to treat with an antibiotic.  Utilization of the Fuchs criteria in this manner 
was a modification of their original use, which was to confirm a clinician’s decision to treat with 
IV antibiotics for a respiratory (as opposed to other) event.  In addition to those patients meeting 
this modified Fuchs endpoint, patients were considered to have experienced an exacerbation if 
they discontinued from the study early for any reason, died, or received an antipseudomonal 
antimicrobial agent for an event that did not meet the predefined criteria but was determined to be 
an exacerbation for the purposes of the primary endpoint by an independent, blinded, 
exacerbation adjudication committee.  Changes in respiratory signs and symptoms were 
systematically collected using the Respiratory Signs and Symptoms Questionnaire (RSSQ) 16.  
The adjudication committee reviewed all instances in which patients received additional 
antipseudomonal antibiotics but did not meet the protocol definition of an acute exacerbation to 
determine if these treatments were associated with exacerbation (further description in e-
supplement).   
Additional endpoints included absolute change from baseline in FEV1 percent predicted, 
change from baseline in CF Questionnaire-Revised (CFQ-R) respiratory symptom score 17, and 
change from baseline in sputum P. aeruginosa density (log10 colony-forming units (CFU) per 
gram sputum).  Adverse events and serious adverse events were captured from baseline to the 
final visit for each patient. In addition to standard adverse event reporting, all worsening of Fuchs 
criteria, as captured on the RSSQ, were captured as adverse events.  
Respiratory secretions (throat swabs or sputum) were collected at all study visits for 
selective bacterial culture by central laboratories.  Distinct P. aeruginosa morphotypes from 
patients were analyzed separately.  Bacterial densities in sputum specimens were determined by 
dilution plating.  
 
Statistics 
Statistical analysis was performed on the intention to treat (ITT) population consisting of 
all randomized patients.  A hierarchical testing procedure was employed; all tests conducted 
subsequent to one in which statistical significance was not demonstrated were to be considered as 
exploratory.   The primary efficacy analysis compared the distributions of the time to 
exacerbation in the treatment groups using a 2-sided stratified (geographic region [US, non-US], 
age [12 to 18 years, > 18 years], and FEV1 percent predicted at Baseline [55%, ≥ 55%]) log rank 
test at the 5% level of significance. The time-to-event distributions in the groups were 
summarized using the Kaplan-Meier method.  Based on the hierarchical testing procedure, if the 
primary efficacy endpoint did not show a statistically significant difference, the treatment 
comparisons for the key secondary endpoints were to be considered as exploratory; hence the 
term “statistical significance” would refer to nominal significance only.  
Secondary analyses of change in FEV1 percent predicted (both absolute and relative 
changes), change in P. aeruginosa sputum density (log10 CFU/g sputum), and change in the 
Respiratory Domain of the CFQ-R from Baseline to Day 28 were each compared between 
treatment groups using linear mixed models for repeated measurements that included terms for 
treatment group (LIS, placebo), visit (Day 14, Day 28), treatment-by-visit interaction, geographic 
region (US, non-US), age (12 to 18 years, > 18 years), and FEV1 percent predicted at Baseline (< 
55%, ≥ 55%).  Additional terms included were Baseline P. aeruginosa sputum density for change 
in P. aeruginosa sputum density and Baseline score for change in the Respiratory Domain of the 
CFQ-R.   
A post-hoc analysis of time to pulmonary exacerbation as defined by either the modified 
Fuchs endpoint or by administration of antipseudomonal antibiotics was performed among patient 
subgroups defined by the number of pulmonary exacerbations treated with intravenous antibiotics 
they had experienced in the prior year.  Hazard ratios (LIS/placebo) and log rank P values were 
determined by Kaplan-Meier survival analysis. 
Due to lack of prior experience with the modified Fuchs study endpoint, sample sizes were 
estimated based upon time-to-need for systemic or inhaled antimicrobials observed for placebo 
patients of a previous LIS study18.  In that prior study, an event-free rate of 0.50 at Day 56 was 
observed.  For the current study, a 2:1 (LIS: placebo) randomization, a maximum follow-up time 
of 56 days, and use of a 2-sided log rank test at the 5% level of significance was determined to 
require 261 patients to obtain 90% power to detect a hazard ratio (HR) of 0.52 (ratio of the risk of 
use of a systemic or inhaled antimicrobial for a pulmonary exacerbation in the LIS arm to the risk 
of same for a pulmonary exacerbation in the placebo arm).  The sample size was subsequently 
increased to account for a secondary endpoint of interest, relative change in FEV1 percent 
predicted, in keeping with the primary endpoint of a Phase 3, open-label, randomized trial to 
compare the safety and efficacy of LIS with TIS over 3 consecutive cycles19.  Accordingly, the 
planned sample size was increased to 330 patients to obtain >90% power to detect an 8.0 
percentage point treatment difference in relative change in FEV1 percent predicted, assuming a 2-
sided test at the 5% level of significance, a standard deviation of 20%, and 2:1 randomization to 
LIS: placebo.  Approximately 415 patients were to be screened to enroll approximately 330 
patients, assuming a 20% screening failure rate.   
 
RESULTS 
Three hundred and thirty patients were randomized in this study; 220 to receive LIS and 
110 placebo.  Most patients completed the study, 95.5% of LIS and 99.1% of placebo patients.  
The disposition and the reasons for discontinuing the study were similar between the treatment 
groups (Figure 1).  Baseline characteristics of the two groups were generally similar with the 
exception of prior year pulmonary exacerbations with the treatment group having a greater 
proportion of subjects with >3 exacerbations compared to the placebo group (p=0.011; Table 1).  
At the randomization visit, P. aeruginosa and Staphylococcus aureus were isolated in 96% and 
51% of patients, respectively.  There were no differences in baseline P. aeruginosa antibiotic 
susceptibility patterns between the two groups (e-supplement Table 1).  Concomitant medications 
were also similar between the two groups at baseline (e-supplement Table 2). The median number 
of inhaled antibiotic courses during the previous year was 6, and 58.7% of the enrolled patients 
had received 6 or more courses. 
 
Efficacy:  
Time to exacerbation 
During the study period, 55.5% of patients receiving LIS and 47.3% of patients receiving 
placebo experienced a protocol-defined pulmonary exacerbation (Figure 2).  There was no 
statistically significant difference in time to protocol-defined pulmonary exacerbations between 
treatment arms (HR= 1.33, 95% CI: 0.96-1.84).  Most patients who met the protocol definition of 
an exacerbation did so as a result of concurrent changes in at least 4 of the 12 Fuchs criteria 
(86.1% of LIS and 84.6% of placebo patients).  The remaining patients considered to have had an 
exacerbation either discontinued from the study early or received an antipseudomonal agent for an 
event that did not meet modified Fuchs criteria but was determined to be an exacerbation for the 
purposes of the primary endpoint by the independent, blinded, exacerbation adjudication 
committee.   
In all, 15.9% of LIS patients and 12.7% of placebo patients met the modified Fuchs 
endpoint for exacerbation but did not receive antipseudomonal agents within 14 days before or 
after meeting criteria.  Conversely, 15.0% of LIS and 25.5% of placebo patients received an 
antipseudomonal agent but did not meet the modified Fuchs endpoint for an exacerbation prior to 
or within 14 days after receiving an antipseudomonal agent (based on Blinded Exacerbation 
Adjudication Committee Summaries).   
 Pulmonary function 
FEV1 percent predicted values were similar in the treatment groups at Baseline.  The LS 
means for absolute change in FEV1 percent predicted from Baseline to Day 28 in the ITT 
population showed an increase in both treatment groups (Figure 3A). The difference between the 
treatment groups favored the LIS group, with an LS mean difference of 1.31 (95% CI 0.27, 2.34; 
Figure 3A).   The LS means for relative change in FEV1 percent predicted from Baseline to Day 
28 in the ITT population showed a difference between the treatment groups favoring the LIS 
group, with an LS mean difference of 2.42 (95% CI 0.53, 4.30, e-supplement Figure 2). 
 
Time to antibiotic requirement and hospitalization. 
The median time to administration of systemic and/or inhaled antipseudomonal 
antimicrobials for patients who met symptoms requirements at the time of administration of the 
antipseudomonal antimicrobials was 59 days in the LIS and 58 days in the placebo group in the 
ITT population.  There was no difference in the distribution of time to administration of the 
antipseudomonal antimicrobials between LIS and placebo (HR = 0.85; 95% CI: 0.61, 1.18), and 
no difference in the time to administration of IV antipseudomonal antimicrobials when symptoms 
requirements were met between LIS and placebo (HR = 0.90; 95% CI: 0.46, 1.78). 
 
Change in P. aeruginosa Sputum Density 
At Day 14, both treatment groups showed a mean reduction in P. aeruginosa sputum 
density.  However, at Day 28, the LIS group showed a mean reduction in P. aeruginosa sputum 
density while the placebo group showed a slight mean increase back to baseline (Figure 3B).  The 
difference in change from baseline to Day 28 between the treatment groups was an LS mean 
difference of -0.63 log10 CFU/g sputum favoring the LIS group (95% CI -0.95, -0.30; Figure 3B). 
 
CFQ-R Respiratory Domain 
Scores on the Respiratory Domain of the CFQ-R were similar in the treatment groups at 
Baseline and both treatment groups had a similar mean increase in CFQ-R Respiratory Domain 
score from Baseline to Day 28.  The results were similar at all time points (e-supplement Figure 
3).  The between-group difference was not significant in the ITT population. 
 
Time to Exacerbation or Antimicrobial Treatment by Prior-Year Treatment History 
 Post-hoc analyses of time to exacerbation and time to treatment with inhaled or systemic 
antipseudomonal antibiotics showed that patients who had no IV-treated exacerbations in the 
prior year tended to have worse outcomes with LIS than placebo (hazard ratios of 2.77 and 1.34), 
although neither hazard ratio was statistically significant by log rank test (Figure 4).  Patients 
receiving LIS with a history of three or more IV-treated exacerbations in the prior year had a 
significantly reduced hazard of treatment with antipseudomonal antimicrobials relative to patients 
receiving placebo (hazard ratio 0.56, P=.028), an effect that was not observed for time to 
exacerbation using the modified Fuchs endpoint (Figure 4). 
 
Safety 
The majority of patients in both treatment groups had Treatment Emergent Adverse 
Events (TEAEs) during the treatment period (Table 2).  With the exception of dysgeusia (taste 
complaint), which was only reported in the LIS group, the TEAE profile was qualitatively similar 
between the treatment groups during the treatment period and the entire study. Excluding disease 
progression of CF pulmonary disease, which represents a pulmonary exacerbation, the other most 
frequent TEAEs were cough and increased sputum. 
Treatment-related dysgeusia was reported during the treatment period for 35.2% of LIS 
and no placebo patients.  Other than dysgeusia, the TEAEs reported for at least 5.0% more LIS 
patients than placebo patients were cough, hemoptysis, pyrexia, and nausea during the entire 
study, while respiratory tract congestion was reported for at least 5.0% more placebo patients than 
LIS patients. The proportions of patients with TEAEs other than dysgeusia during the treatment 
period that were considered by the Investigator to be treatment-related were 27.9% of LIS and 
18.2% of placebo patients.  Most of the TEAEs during the study were mild or moderate; no deaths 
or life-threatening TEAEs were reported. 
Excluding disease progression, treatment-emergent serious adverse events (SAEs) were 
reported for 3.2% of LIS and no placebo patients.  TEAEs led to discontinuation of the study for 
1.8% of LIS patients and 0.9% of placebo patients; these events were disease progression and 
dysgeusia.  The proportion of patients who discontinued Study Drug due to TEAEs, which 
included patients who required antimicrobial agents because of worsening respiratory symptoms 
or exacerbation, was 14.6% in the LIS group (including 9.6% due to disease progression and 
2.3% due to dysgeusia) and 12.7% in the placebo group (including 11.8% due to disease 
progression). 
Fluoroquinolone class effects associated with systemic administration were uncommon in 
this study.  No TEAEs were reported in this study that were related to myasthenia gravis, severe 
cutaneous adverse reactions (e.g., phototoxicity), convulsions, peripheral neuropathy, 
psychosis/psychotic disorders, ocular toxicity (e.g., retinal detachment), or Clostridium difficile-
associated diarrhea/pseudomembranous colitis.  The incidence of arthralgia was low and similar 
between treatment groups (3.2% of LIS patients and 2.7% placebo) and one LIS-treated patient 
had tendonitis; however, there were no reports of tendon rupture.  One LIS-treated patient had 
prolonged QT interval that occurred on Study Day 53, more than 3 weeks after last LIS treatment. 
Blood glucose increased or hyperglycemia was reported for 3.2% of LIS and 3.6% of placebo 
patients, and all of these patients had a prior history of diabetes mellitus.  Blood glucose 
decreased or hypoglycemia was reported for a single patient (0.9%) in each treatment group. 
 
DISCUSSION 
 The study did not achieve its primary endpoint of demonstrating superiority of LIS over 
placebo in the time to a pulmonary exacerbation, but did show superiority over placebo in key 
secondary endpoints including improvement in lung function (FEV1 % predicted) and reduction 
in bacterial density in the sputum.  These latter observations are consistent with other studies of 
LIS compared to placebo18 and tobramycin inhalation solution (TIS)19 in the treatment of subjects 
with CF and chronic P. aeruginosa infection.  The former observation was an unexpected finding 
given the previous demonstration of a reduction in need for antipseudomonal antibiotics for those 
treated with LIS compared to those on placebo18 and the similarity in time to exacerbation in the 
comparison of LIS to TIS19.   
 There are several possibilities that could explain why the primary endpoint of time to 
exacerbation was not met. These include: the treated patients did not receive sufficient 
concentrations of the antibiotic (analysis of serum levofloxacin concentrations do not support this, 
data not provided), the drug lacks efficacy (improvement in the other key endpoints does not 
support this), the study populations are not actually similar, or that the exacerbation definition 
used in the primary endpoint is inappropriate.  Further examination of these latter two possibilities 
were the justification for post hoc analyses.  
 There is general agreement that a validated exacerbation definition does not exist.  
Previous studies have used clinical criteria (i.e. signs and symptoms) or administration of 
antibiotics as clinical endpoints 21. For this study, an unvalidated modification of the Fuchs 
exacerbation endpoint was used. The original Fuchs exacerbation definition required treatment 
with IV antibiotics and the presence of at least 4 of 12 signs or symptoms.  If study participants 
were not treated with IV antibiotics, or if they were treated but less than 4 of the 12 sign and 
symptom criteria were present, the definition of exacerbation was not met15.  In contrast, our 
“modified Fuchs endpoint” drops the requirement for antibiotic treatment and limits the definition 
to meeting at least 4 of the 12 sign or symptom criteria.  A previous post hoc analysis of the data 
from this study as well as another comparing LIS to TIS19 has suggested that the modified Fuchs 
endpoint is a poor predictor for whether an investigator would ultimately treat with antibiotics, an 
alternative method for defining exacerbation22.   
 Neither the Fuchs nor the modified Fuchs are used clinically in the management of 
patients with CF.  In contrast, although antibiotic treatment may be a more subjective event, it is a 
direct clinical measure of exacerbation diagnosis.  In a separate open-label active comparator 
study, participants randomized to LIS had a significantly lower risk of treatment with 
antipseudomonal antibiotics for an exacerbation than did those participants treated with TIS19.  
Although the comparison of LIS to placebo in this blinded, placebo-controlled study slightly 
favored LIS when time to antibiotic treatment for exacerbation was considered in place of the 
modified Fuchs definition, the effect was not statistically significant.   
 One of the strongest predictors of hazard for treatment with IV antibiotics for pulmonary 
exacerbations among CF patients is the number of such treatments received in the previous 
year23,24.  Patients who experienced 3 or more treatments for exacerbation in the prior year have 
been reported to have a >25 fold increased hazard of future treatment compared to patients who 
were not treated in the prior year, while patients treated once or twice in the prior year had a >4 
fold increased hazard23.  Although participant characteristics were generally similar across 
treatment groups in this study, there was a disproportionate allocation of participants with 3 or 
more exacerbations in the prior year to the LIS group (20% placebo vs. 34.1% LIS, P = 0.011; 
Table 1).  An increased proportion of patients at highest risk for exacerbation in the LIS group 
presumably created a baseline imbalance for exacerbation hazard between groups.  When hazards 
of modified Fuchs endpoint or treatment with antipseudomonal antibiotics were compared post 
hoc among subgroups of similar exacerbation risk to mitigate this imbalance, an interesting 
picture emerged, with an LIS treatment effect (as measured by hazard of antibiotic treatment) 
more likely to be observed among patients at higher risk for exacerbation at study entry (Figure 
4).  A comparable relationship between prior-year exacerbation group and LIS treatment effect 
was not observed for the modified Fuchs endpoint, again highlighting a lack of correlation 
between the modified Fuchs measure and the investigators’ decision to treat with 
antipseudomonal antibiotics. 
 LIS was generally well tolerated. With the exception of dysgeusia, cough, and hemoptysis, 
the safety and tolerability profile of LIS  in this study was generally similar to that seen with 
placebo and consistent with the underlying condition. The low frequency of adverse events that 
are potentially attributable to fluoroquinolone class effects (e.g., tendinopathy, QT prolongation) 
is notable, although the overall exposure to LIS was relatively small to reliably detect uncommon 
adverse events. 
 LIS demonstrated clinical efficacy by a reduction in bacterial density and an increase in 
lung function.  Although it did not meet its primary outcome of reduction in exacerbations 
overall, in those patients with a prior history of frequent exacerbations, it may also increase the 
time to antibiotic treatment for pulmonary exacerbations.  Given its proven safety and tolerability 
record, LIS demonstrates promise as a therapy for some patients with CF and chronic P 
aeruginosa infection of the airways. 
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FIGURE LEGENDS 
Figure 1. Patient disposition 
Figure 2. Time to protocol-defined exacerbation by treatment group. Gray boxes denotes on-
treatment period. Solid circles and lines denote LIS, open circles and dashed lines denote TIS.  
Circles represent times at which patients were censored from the analysis. 
Figure 3. Mean absolute change from baseline in FEV1 % predicted and change from baseline in 
sputum P. aeruginosa density by treatment group.  Shaded area denotes on-treatment periods. 
Solid circles and lines denote LIS, open circles and dashed lines denote placebo.  Bars represent 
standard errors.  Panel A: Mean absolute change from baseline in FEV1% predicted. Panel B: 
Mean change from baseline in log10 P. aeruginosa colony-forming units per gram sputum.  
Differences between treatment groups were statistically significant at Day 28. LS=least squares. 
Figure 4. Post hoc hazard ratios (LIS patients/placebo patients) for modified Fuchs exacerbation 
or treatment with antipseudomonal antibiotics stratified by prior IV-treated exacerbation 
subgroups. Hazard ratios were derived using the Kaplan-Meier survival method. Closed circles 
show results for the entire study population.  Open circles show results for patient subgroups 
defined by the number of IV-treated exacerbations patients had experienced in the prior year. Bars 
show 95% confidence intervals and P values are derived from log rank tests. 
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Tables	  
Table	  1:	  Demographics	  at	  baseline	  (Safety	  population)	  
	   Placebo	  (n=110)	   LIS	  (n=219)	  
Age,	  years	   	   	  
	  	  	  	  Mean	  (SD)	   28.8	  (10.9)	   29.4	  (10.3)	  
	  	  	  	  Median	   27.0	   28.0	  
	  	  	  	  >18	  years	   94	  (85.5%)	   184	  (84.0%)	  
Male	  Sex,	  N	  (%)	   63	  (57.3%)	   114	  (52.1%)	  
US	  Patients,	  N	  (%)	   98	  (89.1%)	   193	  (88.1%)	  
FEV1	  percent	  predicted	   	   	  
	  	  	  	  Mean	  (SD)	   56.3	  (15.9)	   56.6	  (15.7)	  
	  	  	  	  Median	   57.6	   57.3	  
	  	  	  	  <55,	  N	  (%)	   52	  (47.3%)	   100	  (45.7%)	  
BMI,	  kg/m2	   	   	  
	  	  	  	  Mean	  (SD)	   22.1	  (3.79)	   22.6	  (3.95)	  
	  	  	  	  Median	   21.7	   21.8	  
Inhaled	  antibiotic	  courses	  during	  previous	  year	  
	  	  	  	  Mean	  (SD)	   6.0	  (2.77)	   5.9	  (2.65)	  
	  	  	  	  Median	   6.0	   6.0	  
	  	  	  	  <2,	  N	  (%)	   5	  (4.5%)	   14	  (6.4%)	  
	  	  	  	  3,	  N	  (%)	   13	  (11.8%)	   26	  (11.9%)	  
	  	  	  	  4,	  N	  (%)	   19	  (17.3%)	   25	  (11.4%)	  
	  	  	  	  5,	  N	  (%)	   7	  (6.4%)	   27	  (12.3%)	  
	  	  	  	  >6,	  N	  (%)	   66	  (60.0%)	   127	  (58.0%)	  
Prior-­‐year	  pulmonary	  exacerbations	  
	  
	  
	   	  
	  	  	  	  0,	  N	  (%)	   21	  (19.1%)	   44	  (20.0%)	  
	  	  	  	  1-­‐2,	  N	  (%)	   67	  (60.9%)	   101	  (45.9%)	  
	  	  	  	  >3,	  N	  (%)	   22	  (20.0%)	   75	  (34.1%)	  
Baseline	  pathogen	  isolation,	  N	  (%)	   	   	  
	  	  	  	  P	  aeruginosa	   105	  (95.5%)	   211	  (96.3%)	  
	  	  	  	  S	  aureus	   58	  (52.7%)	   110	  (50.2%)	  
	  	  	  	  Methicillin	  resistant	  S	  aureus	   22	  (20.0%)	   56	  (25.6%)	  
	  	  	  	  S	  maltophilia	   10	  (9.1%)	   17	  (7.8%)	  
	  	  	  	  A	  xylosoxidans	   8	  (7.3%)	   7	  (3.2%)	  
	  	  	  	  B	  cepacia	  complex	   3	  (2.7%)	   4	  (1.8%)	  
	  
	   	  
Table	  2:	  Treatment	  Emergent	  Adverse	  Events	  (entire	  study)	  
	   Placebo	  	  
N=110	  
LIS	  
N=219	  
Patients	  Reporting	  at	  Least	  1	  Adverse	  Event	   108	  (98.2%)	   204	  (97.7%)	  
Respiratory,	  thoracic	  and	  mediastinal	  disorders	  
	  	  	  Cough	   51	  (46.4%)	   124	  (56.6%)	  
	  	  	  Sputum	  increased	   42	  (38.2%)	   91	  (41.6%)	  
	  	  	  Respiratory	  tract	  congestion	   39	  (35.5%)	   67	  (30.6%)	  
	  	  	  Increased	  viscosity	  of	  bronchial	  secretion	   21	  (19.1%)	   44	  (20.1%)	  
	  	  	  Paranasal	  sinus	  hypersecretion	   18	  (16.4%)	   37	  (16.9%)	  
	  	  	  Haemoptysis	   10	  (9.1%)	   35	  (16.0%)	  
	  	  	  Sputum	  discoloured	   15	  (13.6%)	   23	  (10.5%)	  
	  	  	  Dyspnoea	  exertional	   11	  (10.0%)	   26	  (11.9%)	  
	  	  	  Oropharyngeal	  pain	   7	  (6.4%)	   10	  (4.6%)	  
	  	  	  Rales	   4	  (3.6%)	   12	  (5.5%)	  
	  	  	  Dyspnoea	   5	  (5.6%)	   8	  (4.4%)	  
General	  disorders	  and	  administration	  site	  conditions	  
	  	  	  Disease	  progression	   45	  (40.9%)	   95	  (43.4%)	  
	  	  	  Fatigue	   22	  (20.0%)	   42	  (19.2%)	  
	  	  	  Exercise	  tolerance	  decreased	   11	  (10.0%)	   28	  (12.8%)	  
	  	  	  Pyrexia	   2	  (1.8%)	   16	  (7.3%)	  
Investigations	  
	  	  	  Weight	  decreased	   21	  (19.1%)	   36	  (16.4%)	  
	  	  	  Forced	  expiratory	  volume	  decreased	   10	  (9.1%)	   21	  (9.6%)	  
	  	  	  Blood	  glucose	  decreased	   1	  (0.9%)	   1	  (0.4%)	  
Nervous	  system	  disorders	  
	  	  	  Dysgeusia	   0	  	   77	  (35.2%)	  
	  	  	  Sinus	  headache	   17	  (15.5%)	   26	  (11.9%)	  
	  	  	  Headache	   3	  (2.7%)	   14	  (6.4%)	  
Infections	  and	  infestations	  
	  	  	  Sinusitis	   6	  (5.5%)	   10	  (4.6%)	  
Gastrointestinal	  disorders	  
	  	  	  Nausea	   1	  (0.9%)	   14	  (6.4%)	  
Musculoskeletal	  and	  connective	  tissue	  disorders	  
	  	  	  Arthralgia	   3	  (2.7%)	   7	  (3.2%)	  
Metabolism	  and	  nutrition	  disorders	  
	  	  	  Decreased	  appetite	   12	  (10.9%)	   22	  (10.0%)	  
	  
	   	  
 
